Explore
Validate
LearnNB100-55744
antibody from Novus Biologicals
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-55744 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-55744, RRID:AB_838156
- Product name
- Rabbit Polyclonal TRAILR2/TNFRSF10B Antibody
- Antibody type
- Polyclonal
- Description
- Protein G purified.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Store at -20C. Avoid freeze-thaw cycles.
Submitted references TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9.
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.
The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2591-604
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 1;16(9):2591-604
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M, Georgakis GV, Rahmani M, Beer D, Younes A
European journal of cancer (Oxford, England : 1990) 2006 Mar;42(4):542-7
European journal of cancer (Oxford, England : 1990) 2006 Mar;42(4):542-7
3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.
Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S
Carcinogenesis 2006 Apr;27(4):717-28
Carcinogenesis 2006 Apr;27(4):717-28
Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL, Zou WY, Song LH, Wei W
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Cancer chemotherapy and pharmacology 2005 Feb;55(2):189-96
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A
British journal of haematology 2005 Aug;130(4):501-10
British journal of haematology 2005 Aug;130(4):501-10
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY
Cancer research 2004 Oct 15;64(20):7570-8
Cancer research 2004 Oct 15;64(20):7570-8
Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9.
Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS
Cell death and differentiation 2004 May;11(5):583-7
Cell death and differentiation 2004 May;11(5):583-7
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.
Jin Z, McDonald ER 3rd, Dicker DT, El-Deiry WS
The Journal of biological chemistry 2004 Aug 20;279(34):35829-39
The Journal of biological chemistry 2004 Aug 20;279(34):35829-39
The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation.
Dandrea T, Hellmold H, Jonsson C, Zhivotovsky B, Hofer T, Wärngård L, Cotgreave I
Free radical biology & medicine 2004 Apr 1;36(7):881-96
Free radical biology & medicine 2004 Apr 1;36(7):881-96
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis.
Koyama S
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Journal of gastroenterology and hepatology 2003 Jul;18(7):763-70
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK
Cancer research 2003 Apr 1;63(7):1712-21
Cancer research 2003 Apr 1;63(7):1712-21
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Zhang HG, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT, Hsu HC, Mountz JD
Journal of virology 2002 Jun;76(11):5692-700
Journal of virology 2002 Jun;76(11):5692-700
Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Zhang HG, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT, Hsu HC, Mountz JD
Journal of virology 2002 Jun;76(11):5692-700
Journal of virology 2002 Jun;76(11):5692-700
Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S, Koike N, Adachi S
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Journal of cancer research and clinical oncology 2002 Feb;128(2):73-9
Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
Eid MA, Lewis RW, Kumar MV
Molecular cancer therapeutics 2002 Aug;1(10):831-40
Molecular cancer therapeutics 2002 Aug;1(10):831-40
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Basile JR, Zacny V, Münger K
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S
Cancer research 2001 Jun 15;61(12):4892-900
Cancer research 2001 Jun 15;61(12):4892-900
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF, Bernhard EJ, El-Deiry WS
Oncogene 2001 Aug 2;20(34):4601-12
Oncogene 2001 Aug 2;20(34):4601-12
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K, Fisher MJ, Xu SQ, el-Deiry WS
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Feb;6(2):335-46
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Feb;6(2):335-46
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: TRAIL R2/TNFRSF10B Antibody - Azide Free [NB100-55744] - Analysis of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL R2/TNFRSF10B at 5 ug/ml.
